Defining the Role of Oral SERDs in Frontline Metastatic Breast Cancer

Question remains whether certain biomarkers will define patients who may benefit

martedì 23 giugno 2026 New tab

450 words~2 min read

— Question remains whether certain biomarkers will define patients who may benefit

by Gregory Laub, Senior Director, Video, MedPage Today

June 23, 2026

• 2 min read

At the American Society of Clinical Oncology (ASCO) meeting, results from the phase III persevERA BC trial did not show a statistically significant progression-free survival (PFS) benefit with the investigational oral selective estrogen receptor degrader (SERD) giredestrant plus palbociclib (Ibrance) versus standard endocrine therapy plus palbociclib in first-line hormone receptor-positive, HER2-negative metastatic breast cancer.